Clinical Trials Logo

Clinical Trial Summary

This is a research study about improving our diagnostic method for small intestinal bacterial overgrowth (SIBO). Patients undergoing Standard of Care (SOC) Endoscopically assisted glucose breath test (EAGBT) will undergo upper endoscopy and glucose breath tests. In this study, investigators wish to utilize Nuclear Medicine techniques to locate where the glucose solution that is administered during EAGBT is being consumed by bacteria is in the small bowel when it detects SIBO.


Clinical Trial Description

Small intestinal bacterial overgrowth (SIBO) is characterized by bloating, gas, distention, and diarrhea due to colonization and an excessive amount of bacteria in the small bowel. Distal SIBO is the presence of excessive amounts of bacteria in the distal jejunum and/or ileum. Diagnosis of SIBO requires either duodenal aspirate with culture analysis or more commonly with breath hydrogen/methane testing. Hydrogen breath testing often uses either oral glucose or lactulose solutions. If bacteria are present in the small bowel they will ferment glucose or lactulose, producing hydrogen or methane as a byproduct. These gases are absorbed into the bowel, and then eliminated via pulmonary expiration. By detecting a rise in breath H2 and CH4 values compared to baseline, SIBO can be diagnosed. However, after oral ingestion, the majority of the glucose substrate is absorbed in the duodenum and proximal jejunum. Therefore, Glucose breath test (GBT) is good for the detection of proximal SIBO, but misses distal SIBO.

Investigators have recently shown that glucose administration into the distal duodenum through upper endoscopy has a higher positive yield for SIBO in patients with negative oral GBT. However, it is unclear if the rise in breath H2 or CH4 is because of glucose fermentation by bacteria in the distal small bowel or from fermentation by bacteria in the colon, i.e. false-positive test. Study objective here is to administer a radio-labeled glucose solution into the duodenum via an endoscopically placed nasoduodenal tube, and then determine if the rise in breath hydrogen and/or methane correlates with the location of the isotopic glucose solution in the bowel by simultaneous nuclear imaging. Results of breath testing will also be compared with duodenal aspirate/cultures taken at the time of endoscopy. Clinical response to treatment will be assessed on follow up. ;


Study Design


Related Conditions & MeSH terms

  • Small Intestinal Bacterial Overgrowth

NCT number NCT04499742
Study type Observational
Source Augusta University
Contact Tennekoon Karunaratne, MD, PhD
Phone 7067211968
Email tkarunaratne@augusta.edu
Status Recruiting
Phase
Start date January 21, 2019
Completion date December 14, 2021

See also
  Status Clinical Trial Phase
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02251483 - Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth N/A
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Completed NCT06162702 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) N/A
Completed NCT00680836 - Gulf War Digestive Health Study N/A
Enrolling by invitation NCT03659175 - Characteristic of Intestinal Flora in Male Elderly With Small Intestinal Bacterial Overgrowth
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Terminated NCT04316806 - Effect of a Probiotic Formula on Reducing SIBO in IBS Patients N/A
Completed NCT05765994 - Small Intestinal Bacterial Overgrowth in Critically Ill Patients
Not yet recruiting NCT06317441 - The Safety and Efficacy of a Probiotic Intervention on SIBO and Related Gastrointestinal Symptoms N/A
Recruiting NCT05967871 - Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth Phase 1
Enrolling by invitation NCT04501380 - Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) Phase 2
Completed NCT03692299 - Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis Phase 4
Completed NCT05915767 - Therapeutic Effect of Olive Leaf Tea on SIBO N/A
Recruiting NCT04910815 - Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. N/A
Enrolling by invitation NCT02458781 - Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth Phase 4
Enrolling by invitation NCT01822470 - Small Intestinal Bacterial Overgrowth: A Prospective Registry
Terminated NCT02439307 - Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial N/A
Completed NCT03216239 - SIBO & SIFO After Colectomy
Completed NCT00619970 - Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth? N/A